Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucidinostat and Apatinib in Relapsed or Refractory Osteosarcoma
NCT06125171Phase 2Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in osteosarcoma (OS). Primary endpoint: 6-month Progression-Free Survival Rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06125171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125171.